Table 3.

Risk of all-cause mortality, breast cancer–specific mortality, and additional breast cancer event by inflammatory status using serum CRP concentrations in breast cancer survivors in the WHEL study

Model 1aModel 2bModel 3c
Models of association by serum CRPNo. of eventsNHR95% CIPtrendHR95% CIPtrendHR95% CIPtrend
All-cause mortality
Inflammatory status<0.0010.0050.006
 No inflammation, CRP <1 mg/L619811.00Referent1.00Referent1.00Referent
 Low, CRP 1–3 mg/L669331.010.71–1.440.990.69–1.430.980.68–1.42
 Moderate, CRP >3 to <10 mg/L737501.410.99–2.001.320.89–1.961.300.88–1.93
 Acute, CRP ≥10 mg/L362552.121.38–3.231.961.22–3.131.921.20–3.08
lnCRP2362,9191.211.09–1.341.191.06–1.341.191.05–1.34
Breast cancer mortality
Inflammatory status0.0040.030.03
 No inflammation519811.00Referent1.00Referent1.00Referent
 Low Inflammation569331.100.75–1.621.070.71–1.591.070.72–1.59
 Moderate inflammation537501.330.90–1.971.220.78–1.901.220.78–1.91
 Acute inflammation282552.101.30–3.381.911.13–3.231.881.11–3.18
lnCRP1882,9191.181.06–1.331.161.02–1.321.161.01–1.31
Additional breast cancer events
Inflammatory status0.010.020.03
 No inflammation1269811.00Referent1.00Referent1.00Referent
 Low inflammation1269331.060.82–1.361.080.82–1.401.060.82–1.38
 Moderate inflammation1117501.120.86–1.451.140.85–1.531.120.83–1.50
 Acute inflammation542551.671.20–2.311.691.17–2.431.651.15–2.38
lnCRP4172,9191.121.04–1.211.141.04–1.241.131.03–1.24
  • aAdjusted for age (continuous), time since diagnosis, disease stage, disease grade, and race–ethnicity.

  • bAdjusted for age (continuous), time since diagnosis, disease stage, disease grade, race–ethnicity, and BMI (categorical).

  • cAdjusted for age (continuous), time since diagnosis, disease stage, disease grade, race–ethnicity, BMI (categorical), anti-estrogen use, and ER/PR status.